Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.61 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.61 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 5/20 | 0.42 |
| ▸ | ACE | P12821 | 3/20 | 0.42 |
| ▸ | ECE1 | P42892 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL6014792 | 1.00 | PTGS1 (0.61) | PTGS1SLC7A11GSTK1ALDH1A1MAPT | |
| SCHEMBL27574429 | 0.94 | PTGS1 (0.53) | PTGS1SLC7A11GSTK1ALDH1A1MAPT | |
| SCHEMBL11766266 | 0.94 | PTGS1 (0.53) | PTGS1SLC7A11GSTK1ALDH1A1MAPT | |
| SCHEMBL213626 | 0.94 | PTGS1 (0.53) | PTGS1SLC7A11GSTK1ALDH1A1MAPT | |
| SCHEMBL213625 | 0.94 | PTGS1 (0.53) | PTGS1SLC7A11GSTK1ALDH1A1MAPT | |
| SCHEMBL27922237 | 0.92 | PTGS1 (0.51) | PTGS1SLC7A11GSTK1ALDH1A1MAPT | |
| SCHEMBL27922239 | 0.92 | PTGS1 (0.51) | PTGS1SLC7A11GSTK1ALDH1A1MAPT | |
| L-Homocysteine SCHEMBL7201153 | 0.90 | PTGS1 (0.58) | PTGS1SLC7A11GSTK1ALDH1A1MAPT | |
| Homocysteine SCHEMBL28053941 | 0.90 | PTGS1 (0.58) | PTGS1SLC7A11GSTK1ALDH1A1MAPT | |
| SCHEMBL3393046 | 0.89 | ALDH1A1 (0.52) | PTGS1SLC7A11GSTK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081472-B2 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | K. U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2006-07-25 | — | — | US | claimed |
| US-20040053911-A1 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-03-18 | — | — | US | claimed |
| EP-1343758-A1 | SUBSTITUTED BIS-INDOLE DERIVATIVES USEFUL AS CONTRAST AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES FOR PRODUCING THEM | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2003-09-17 | — | — | EP | claimed |
| WO-2002038546-A1 | SUBSTITUTED BIS-INDOLE DERIVATIVES USEFUL AS CONTRAST AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES FOR PRODUCING THEM | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2002-05-16 | — | — | WO | claimed |
| EP-0998946-A1 | Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-05-10 | — | — | EP | claimed |
| WO-2000009169-A1 | NON-PORPHYRIN COMPOUND FOR USE AS A DIAGNOSTICUM AND/OR PHARMACEUTICAL | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-02-24 | — | — | WO | claimed |
| US-7081472-B2 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | K. U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2006-07-25 | — | — | US | disclosed |
| US-20040053911-A1 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-03-18 | — | — | US | disclosed |
| EP-1343758-A1 | SUBSTITUTED BIS-INDOLE DERIVATIVES USEFUL AS CONTRAST AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES FOR PRODUCING THEM | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002038546-A1 | SUBSTITUTED BIS-INDOLE DERIVATIVES USEFUL AS CONTRAST AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES FOR PRODUCING THEM | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053911-A1 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | IDO1, IDO2, CNR1 | PTGS1 1041/4885SLC7A11 2289/4885GSTK1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.